Cory A Perugino1, Sultan B AlSalem2, Hamid Mattoo3, Emanuel Della-Torre4, Vinay Mahajan5, Gayathri Ganesh3, Hugues Allard-Chamard3, Zachary Wallace6, Sydney B Montesi7, Johannes Kreuzer8, Wilhelm Haas8, John H Stone6, Shiv Pillai9. 1. Division of Rheumatology, Allergy, & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass. 2. Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass; Department of Dermatology, King Saud University College of Medicine, Riyadh, Saudi Arabia. 3. Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass. 4. Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS-San Raffaele Scientific Institute, Milan, Italy. 5. Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass; Division of Pathology, Brigham and Women's Hospital, Boston, Mass. 6. Division of Rheumatology, Allergy, & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 7. Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, Mass. 8. Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Charlestown, Mass. 9. Division of Rheumatology, Allergy, & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Ragon Institute of MGH, MIT and Harvard, Cambridge, Mass. Electronic address: spillai@mgh.harvard.edu.
Abstract
BACKGROUND: The antigenic trigger that drives expansion of circulating plasmablasts and CD4+ cytotoxic T cells in patients with IgG4-related disease (IgG4-RD) is presently unknown. OBJECTIVE: We sought to sequence immunoglobulin genes from single-cell clones of dominantly expanded plasmablasts and generate recombinant human mAbs to identify relevant antigens in patients with IgG4-RD by using mass spectrometry. METHODS: Paired heavy and light chain cDNAs from dominant plasmablast clones were expressed as mAbs and used to purify antigens by using immunoaffinity chromatography. Affinity-purified antigens were identified by using mass spectrometry and validated by means of ELISA. Plasma levels of the antigen of interest were also determined by using ELISA. RESULTS: mAbs expressed from the 2 dominant plasmablast clones of a patient with multiorgan IgG4-RD stained human pancreatic tissue sections. Galectin-3 was identified as the antigen specifically recognized by both mAbs. Anti-galectin-3 autoantibody responses were predominantly of the IgG4 isotype (28% of the IgG4-RD cohort, P = .0001) and IgE isotype (11% of the IgG4-RD cohort, P = .009). No significant responses were seen from the IgG1, IgG2, or IgG3 isotypes. IgG4 anti-galectin-3 autoantibodies correlated with increased plasma galectin-3 levels (P = .001), lymphadenopathy (P = .04), total IgG level increase (P = .05), and IgG4 level increase (P = .03). CONCLUSION: Affinity chromatography using patient-derived mAbs identifies relevant autoantigens in patients with IgG4-RD. IgG4 galectin-3 autoantibodies are present in a subset of patients with IgG4-RD and correlate with galectin-3 plasma levels. The marked increases in levels of circulating IgG4 and IgE observed clinically are, at least in part, caused by the development of IgG4- and IgE-specific autoantibody responses.
BACKGROUND: The antigenic trigger that drives expansion of circulating plasmablasts and CD4+ cytotoxic T cells in patients with IgG4-related disease (IgG4-RD) is presently unknown. OBJECTIVE: We sought to sequence immunoglobulin genes from single-cell clones of dominantly expanded plasmablasts and generate recombinant human mAbs to identify relevant antigens in patients with IgG4-RD by using mass spectrometry. METHODS: Paired heavy and light chain cDNAs from dominant plasmablast clones were expressed as mAbs and used to purify antigens by using immunoaffinity chromatography. Affinity-purified antigens were identified by using mass spectrometry and validated by means of ELISA. Plasma levels of the antigen of interest were also determined by using ELISA. RESULTS: mAbs expressed from the 2 dominant plasmablast clones of a patient with multiorgan IgG4-RD stained humanpancreatic tissue sections. Galectin-3 was identified as the antigen specifically recognized by both mAbs. Anti-galectin-3 autoantibody responses were predominantly of the IgG4 isotype (28% of the IgG4-RD cohort, P = .0001) and IgE isotype (11% of the IgG4-RD cohort, P = .009). No significant responses were seen from the IgG1, IgG2, or IgG3 isotypes. IgG4 anti-galectin-3 autoantibodies correlated with increased plasma galectin-3 levels (P = .001), lymphadenopathy (P = .04), total IgG level increase (P = .05), and IgG4 level increase (P = .03). CONCLUSION: Affinity chromatography using patient-derived mAbs identifies relevant autoantigens in patients with IgG4-RD. IgG4 galectin-3 autoantibodies are present in a subset of patients with IgG4-RD and correlate with galectin-3 plasma levels. The marked increases in levels of circulating IgG4 and IgE observed clinically are, at least in part, caused by the development of IgG4- and IgE-specific autoantibody responses.
Authors: Lili Yu; Willem P T Ruifrok; Maxi Meissner; Eelke M Bos; Harry van Goor; Bahram Sanjabi; Pim van der Harst; Bertram Pitt; Irwin J Goldstein; Jasper A Koerts; Dirk J van Veldhuisen; Ruud A Bank; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer Journal: Circ Heart Fail Date: 2012-12-10 Impact factor: 8.790
Authors: Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Francoise Poirier; Francesco P Russo; John P Iredale; Christopher Haslett; Kenneth J Simpson; Tariq Sethi Journal: Proc Natl Acad Sci U S A Date: 2006-03-20 Impact factor: 11.205
Authors: Hang Liu; Cory A Perugino; Musie Ghebremichael; Zachary S Wallace; Sydney B Montesi; John H Stone; Shiv Pillai Journal: Arthritis Rheumatol Date: 2020-02-10 Impact factor: 10.995
Authors: K Kamata; T Watanabe; K Minaga; A Hara; I Sekai; Y Otsuka; T Yoshikawa; A-M Park; M Kudo Journal: Clin Exp Immunol Date: 2020-09-21 Impact factor: 4.330
Authors: Justin A Jarrell; Matthew C Baker; Cory A Perugino; Hang Liu; Michelle S Bloom; Takashi Maehara; Heidi H Wong; Tobias V Lanz; Julia Z Adamska; Sarah Kongpachith; Jeremy Sokolove; John H Stone; Shiv S Pillai; William H Robinson Journal: J Allergy Clin Immunol Date: 2021-05-08 Impact factor: 10.793
Authors: Hugues Allard-Chamard; Faisal Alsufyani; Naoki Kaneko; Kelly Xing; Cory Perugino; Vinay S Mahajan; Joseph L Wheat; George S Deepe; James Loyd; Shiv Pillai Journal: J Immunol Date: 2020-12-16 Impact factor: 5.422